Patents by Inventor Selvarangan Ponnazhagan

Selvarangan Ponnazhagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
    Patent number: 7052692
    Abstract: The present invention identifies a protein, designated the D-sequence-binding protein (D-BP), is phosphorylated at tyrosine residues and blocks AAV-mediated transgene expression in infected cells by inhibiting the leading strand viral DNA synthesis. More particularly, the present invention demonstrates that D-BP is phosphorylated by EGF-R protein tyrosine kinase. Methods of increasing transcription and promoting replication of transgenes exploiting this information are disclosed herein.
    Type: Grant
    Filed: September 1, 1998
    Date of Patent: May 30, 2006
    Assignee: Advanced Research & Technology Institute
    Inventors: Arun Srivastava, Keyun Qing, Xu-Shan Wang, Selvarangan Ponnazhagan, Anil Bajpai
  • Methods and compositions for liver specific delivery of therapeutic molecules using recombinant AAV vectors
    Publication number: 20030166284
    Abstract: Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.
    Type: Application
    Filed: March 28, 2002
    Publication date: September 4, 2003
    Applicant: Chiron Corporation
    Inventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Schloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
  • AAV vectors
    Patent number: 6521225
    Abstract: The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: February 18, 2003
    Assignees: Chiron Corporation, Advanced Research and Technology Institute
    Inventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Chloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki
  • Methods and compositions for liver specific delivery of therapeutic molecules using recombinant AAV vectors
    Publication number: 20010051611
    Abstract: Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.
    Type: Application
    Filed: July 24, 2001
    Publication date: December 13, 2001
    Applicant: Chiron Corporation.
    Inventors: Arun Srivastava, Selvarangan Ponnazhagan, Robert H. Schloemer, Xu-Shan Wang, Mervin C. Yoder, Shang-Zhen Zhou, Jaime Escobedo, Varavani Dwarki